Rosalie Griffin, Julia Erin Wiedmeier-Nutor, Sameer A Parikh, Chantal E McCabe, Daniel R O'Brien, Nicholas J Boddicker, Geffen Kleinstern, Kari G Rabe, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Wei Ding, Jose F Leis, Paul Joseph Hampel, Timothy G Call, Daniel Van Dyke, Neil E Kay, James R Cerhan, Huihuang Yan, Susan L Slager, Esteban Braggio
TP53 aberrations, including mutations and deletion of 17p13, are important adverse prognostic markers in chronic lymphocytic leukemia (CLL) but are less studied in high count monoclonal B-cell lymphocytosis (HCMBL), an asymptomatic pre-malignant stage of CLL. Here we estimated the prevalence and impact of TP53 aberrations in 1,230 newly diagnosed treatment-naïve individuals (849 CLL, 381 HCMBL). We defined TP53 state as: wild-type (no TP53 mutations and normal 17p), single-hit (del(17p) or one TP53 mutation), or multi-hit (TP53 mutation and del(17p), TP53 mutation and loss of heterozygosity, or multiple TP53 mutations)...
March 6, 2023: Blood Advances